Value through Innovation23 September 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

25.02.2013

Healthcare Innovation World Cup: Call for Breakthrough Ideas to Tackle Diabetes

23.02.2013

Phase III results: tiotropium* Respimat® is effective in symptomatic asthma patients irrespective of their allergic status

21.02.2013

New findings from two studies support substantial benefit of Pradaxa® for prevention of recurrent deep vein thrombosis and pulmonary embolism

- For Non-US, Non-UK & Non-Canadian Media Only
14.02.2013

Preventing disease: One billion pigs vaccinated with Ingelvac CircoFLEX®

30.01.2013

FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol* for Maintenance Treatment of COPD

- For Media outside the U.S. and UK
23.01.2013

Boehringer Ingelheim and Ashoka Changemakers Launch Competition to Find Business Models that Transform Health Systems

17.01.2013

Boehringer Ingelheim and the EFSD call for grant applications in diabetes research

17.01.2013

Boehringer Ingelheim enrols first patients in pivotal Phase III interferon-free hepatitis C trial programme

- For media outside of the U.S.A., UK and Canada only
16.01.2013

U.S. FDA Grants Priority Review to Boehringer Ingelheim’s Afatinib* NDA for EGFR Mutation-Positive Advanced NSCLC

- For NON-U.S. Media Only
07.01.2013

Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin

- EX US & UK. Medical Media Only.
07.01.2013

Lilly reassumes sole worldwide development and commercialization rights for novel basal insulin analog

11.12.2012

Boehringer Ingelheim receives EU approval for Metacam® for the relief of pain following dehorning in calves

11.12.2012

Boehringer Ingelheim discontinues Phase II trial in patients with artificial heart valves

- For Non-US, Non-UK & Non-Canadian Media Only
10.12.2012

Boehringer Ingelheim to initiate Phase III study in leukaemia with its compound volasertib* based on positive Phase II results

- For NON-US media only
10.12.2012

Treatment with Pradaxa® associated with better patient outcomes after a major bleeding event compared to warfarin

- For Non-US, Non-UK & Non-Canadian Media Only
05.12.2012

Boehringer Ingelheim and Apexigen sign manufacturing agreement for process development and early stage clinical supply

05.12.2012

New Pradaxa® safety and efficacy data to be featured at ‘Best of ASH’ session

- For Non-US, Non-UK & Non-Canadian Media Only
14.11.2012

Run for diabetes: Boehringer Ingelheim supports ‘Life for a Child’ programme on World Diabetes Day